| 1 |
33903122 | EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma. | 2021 Jun 15 |
2 |
| 2 |
32434184 | Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells. | 2020 |
1 |
| 3 |
30557787 | Biosynthesis of sorafenib coated graphene nanosheets for the treatment of gastric cancer in patients in nursing care. | 2019 Feb |
1 |
| 4 |
31029219 | Sorafenib. | 2019 |
1 |
| 5 |
29188798 | Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling. | 2018 Mar |
1 |
| 6 |
27873490 | EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. | 2017 Jan |
1 |
| 7 |
28450419 | Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells. | 2017 Jul |
1 |
| 8 |
25447203 | Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. | 2015 Feb 1 |
1 |
| 9 |
25862849 | Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. | 2015 Apr |
1 |
| 10 |
25895026 | Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. | 2015 May 20 |
1 |
| 11 |
22006587 | Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. | 2013 Jan |
1 |
| 12 |
23255896 | Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. | 2013 Jan |
1 |
| 13 |
24391798 | BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. | 2013 |
3 |
| 14 |
24460304 | Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. | 2013 |
1 |
| 15 |
21617941 | Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. | 2012 Feb |
3 |
| 16 |
21858812 | Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. | 2012 Aug 1 |
1 |
| 17 |
22278289 | Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. | 2012 Jan 26 |
1 |
| 18 |
22941289 | The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. | 2012 Oct |
3 |
| 19 |
21816375 | Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. | 2011 Aug |
1 |
| 20 |
22206574 | Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. | 2011 Dec 29 |
1 |
| 21 |
19652055 | Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. | 2009 Sep 10 |
1 |
| 22 |
21127754 | Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. | 2008 Nov 1 |
2 |
| 23 |
16133532 | Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. | 2006 May |
1 |
| 24 |
16757355 | Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. | 2006 |
3 |
| 25 |
15655409 | The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. | 2005 Feb |
1 |
| 26 |
16240452 | Targeted agents for the treatment of advanced renal cell carcinoma. | 2005 Dec 1 |
1 |